

1 **Multiple hypervirulent methicillin-sensitive *Staphylococcus aureus* lineages**
2 **contribute towards poor patient outcomes in orthopedic device-related**
3 **infections**

4

5 Virginia Post^{a*}, Ben Pascoe^{b,c,d*}, Evangelos Mourkas^c, Jessica K. Calland^e, Matthew
6 D. Hitchings^f, Christoph Erichsen^g, Julian Fischer^g, Mario Morgenstern^h, R. Geoff
7 Richards^a, Samuel K. Sheppard^{c#} & T. Fintan Moriarty^{a,h#}

8

9 ^aAO Research Institute Davos, Davos, Switzerland

10 ^bCentre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford,
11 Oxford, United Kingdom

12 ^cIneos Oxford Institute of Antimicrobial Research, Department of Biology, University
13 of Oxford, Oxford, United Kingdom

14 ^dFaculty of Veterinary Medicine, Chiang Mai University, Chiang Mai, Thailand

15 ^eOslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo,
16 Norway

17 ^fSwansea University Medical School, Swansea University, Swansea, United Kingdom

18 ^gDepartment of Trauma Surgery, Trauma Centre Murnau, Murnau, Germany

19 ^hDepartment of Orthopedic and Trauma Surgery, University Hospital Basel,
20 Switzerland

21

22 **Running title:** Orthopedic device related *S. aureus* infections

23

24 **#Address correspondence to:** T. Fintan Moriarty, fintan.moriarty@aofoundation.org
25 or Samuel K. Sheppard, samuel.sheppard@biology.ox.ac.uk

26 *VP and BP contributed equally to this work. SKS and TFM contributed equally to this
27 work.

28

29

30 **Abstract**

31 Staphylococci are the most common cause of orthopedic device-related infections
32 (ODRIs), with *Staphylococcus aureus* responsible for a third or more of cases. This
33 prospective clinical and laboratory study investigated the association of genomic and
34 phenotypic variation with treatment outcomes in ODRI isolates. Eighty-six invasive *S.*
35 *aureus* isolates were collected from patients with ODRI, and clinical outcome was
36 assessed after a follow-up examination of 24 months. Each patient was then
37 considered to have been "cured" or "not cured" based on predefined clinical criteria.
38 Whole genome sequencing and molecular characterization identified isolates
39 belonging to globally circulating community- and hospital-acquired pandemic
40 lineages. Most isolates were phenotypically susceptible to methicillin and lacked the
41 *SCCmec* cassette (MSSA), but contained several (hyper) virulence genes, including
42 toxins and biofilm genes. While recognizing the role of the host immune response, we
43 identify characteristics of isolate genomes that, with larger datasets, could help
44 contribute to infection severity or clinical outcome predictions. While this and several
45 other studies reinforce the role antibiotic resistance (e.g., MRSA infection) has on
46 treatment failure, it is important not to overlook MSSA that can cause equally
47 destructive infections and lead to poor patient outcomes.

48

49 **Keywords** *Staphylococcus aureus*; MRSA; MSSA; virulence factors; antibiotic
50 resistance; orthopedic device-related infections.

51

52 **Importance**

53 *Staphylococcus aureus* is a prominent cause of orthopedic device-associated
54 infections, yet little is known about how the infecting pathogen, and specifically the
55 repertoire of genome-encoded virulence factors can impact treatment outcome. Past
56 studies have focused on distinguishing commensal from invasive *S. aureus* isolates
57 but in this study, we aim to investigate traits in infecting isolates that influence patient
58 outcomes. Invasive *S. aureus* isolates were collected from orthopedic-device related
59 infection patients and categorized according to the success of subsequent treatment
60 ("cured" /"not cured"), as determined following hospital discharge two years after
61 initial presentation. Several MSSA hypervirulent clones were associated with a "not
62 cured" clinical outcome. Improved understanding of the bacterial traits associated
63 with treatment failure in ODRI will inform the risk assessment, prognosis, and therapy
64 of these infections.

65

66 Introduction

67 The most challenging complication in orthopedic surgery is orthopedic-device related
68 infection (ODRI), with incidence ranging from 0.7 % to 4.2 % for elective orthopedic
69 surgeries (1–4). Incidence increases to over 30 % following operative fixation of
70 complex open fractures (5, 6). While patient health is a key risk factor (including a
71 high BMI and chronic immunosuppression) for poor treatment outcomes (7, 8), there
72 is evidence that pathogen genetic diversity can be an indicator of patient outcome
73 (9–12). *Staphylococcus aureus* is the most common infecting agent (2, 3, 13–15) and
74 treatment outcome is often complicated by infection with antimicrobial resistant
75 lineages e.g., methicillin-resistant *S. aureus* (MRSA) (8, 16). Combined with high
76 virulence potential, MRSA are difficult to treat and are a global healthcare concern.
77 Despite this, predicting treatment outcomes based on bacterial
78 phenotypes/genotypes remains difficult (8, 10, 11, 17).

79

80 Hypervirulent pandemic clonal lineages have helped spread *S. aureus* around the
81 world and the geographic distribution of many lineages is dynamic, with different
82 lineages dominating infections in specific global regions (18, 19). Waves of MRSA
83 lineages have risen and been replaced since the emergence of MRSA in the 1940s
84 (18, 20). These highly structured populations can be grouped into clonal complexes
85 (CCs) that share five or more alleles at seven multi-locus sequence typing (MLST)
86 loci (21–23). Community-associated MRSA (CA-MRSA) have begun to replace
87 hospital-associated MRSA (HA-MRSA) as the dominant epidemic strains (24). The
88 most prevalent lineages include 5 global community acquired (CA-MRSA) genotypes
89 CC1, CC8, CC30, CC59 and CC80. The most common hospital-acquired lineages
90 are CC5, CC22 (UK), CC239 and CC45 (21–23). Combining MLST with traditional
91 molecular typing techniques such as identification of the staphylococcal cassette
92 chromosome *mec* (SCC*mec*) (25) and *spa* repeat regions (26) can provide a
93 nomenclature to describe relevant epidemic clones can be provided. Lineages can
94 acquire advantageous traits, such as antibiotic resistance, which proliferate in the
95 population through the descendants of successful strains. This likely occurs in many
96 instances, however, the extent of this in the context of ODRI remains to be
97 determined.

98

99 Despite the growing concern of MRSA lineages, MSSA isolates are often the most
100 common in invasive surgery-related infections (27, 28). Convergent evolution in
101 several CA- lineages potentially balances the fitness costs of expressing AMR genes
102 with the acquisition of multiple virulence factors (29–32). Specific genes encoding
103 putative virulence factors in invasive *S. aureus* disease involve evasion of immune
104 defenses, including the ability to adhere to and invade host tissues - essential for
105 ODRI (33, 34). A large body of work has identified many virulence factors, including
106 Microbial Surface Components Recognizing Adhesive Matrix Molecules
107 (MSCRAMMs), the polysaccharide intercellular adhesion (PIA), the Staphylococcal
108 protein A, extracellular proteins such as coagulase, Staphylococcal enterotoxins
109 (SE), exfoliatins (ET), toxic shock syndrome toxin (TSST), staphyloxanthin,
110 hemolysins and Panton Valentine leukocidin (PVL) that have a crucial impact on the
111 pathogenicity of *S. aureus* infections (35–38). Genome-wide association studies have
112 been applied to numerous bacterial species (39, 40), and identified genes or genetic
113 elements associated with disease that transcend clonal patterns of inheritance (not
114 confined to specific lineages) in Staphylococci. Phenotype filtering techniques have
115 attempted to assess patient risk and predict disease outcome from genetic data
116 based on enrichment for disease-associated traits (12, 41–43). GWAS approaches
117 have shown promising disease prediction results (31, 43, 44), as well as AMR
118 profiles (45). As in other bacterial species (46–48), a better understanding of genome
119 and transcriptome variation in hypervirulent infection types shows promise for our
120 ability to predict disease severity in Staphylococci (49).

121

122 In this study we investigate the association between treatment outcomes determined
123 2 years post-operatively in patients with *S. aureus* ODRI and phenotypic and
124 genotypic features of the infecting pathogen. Building on recent studies aiming to
125 predict *S. aureus* virulence from genome sequence (43, 44), we aim to distinguish
126 high risk lineages, isolates and genes. These features were correlated with mortality
127 rate in a simplified virulence model using *Galleria mellonella*.

128

129 **Results**

130 *S. aureus* isolates were collected from 86 patients undergoing operative revision of
131 an ODRI (**Supplementary table S1**). Patient outcomes were assessed after a 2-year
132 follow-up period and "cured" patients were free of infection, surgical and systemic
133 antibiotic therapy had ceased with function of the affected joint or limb restored. If
134 one or more of these parameters was negative, patients were considered to have
135 had a "not cured" outcome (8, 12). Most patients enrolled in the study received
136 successful treatment and were among the "cured" cohort (**Table 1**; n= 65/86; 75.6%).
137 Treatment was unsuccessful in 21 patients (n=21/86; 24.4% "not-cured") and multiple
138 revision surgeries were necessary for nearly all patients (n=83/86; 96.5%).

139

140 **Host-associated risk factors**

141 Extensive patient data, types of implanted devices and clinical presentation were
142 recorded for each infected patient (**Table 1**). Additionally, the effects of patient co-
143 morbidities (such as diabetes or obesity), fracture types or the time of symptoms
144 onset on treatment outcome were analyzed (**Table 2**). None of these prognostic
145 factors alone significantly decreased cure rate.

146

147 **Multiple lineages contribute to poor patient outcome**

148 A maximum-likelihood phylogeny was constructed based on shared coding
149 sequences, present in 95% or more isolates (**Figure 1A**; **Supplementary table S1**).
150 The collected isolates were genetically diverse and represented 19 different
151 sequence types (STs) (**Figure 1B**) based on the 7 loci scheme for *S. aureus* and
152 could be grouped into 18 clonal complexes (CCs) based on 5 or more shared MLST
153 loci (21). No clear clustering was observed between "cured" and "not-cured" isolates.
154 Consistent with other European surveillance efforts, six of our seven most common
155 lineages matched common pandemic *S. aureus* lineages (CC5, CC8, CC22, CC30,
156 CC45 and CC59) previously identified by the ESCMID study group (collected from 26
157 European countries between 2006-7) (50). Our isolates predominantly lacked the
158 *SCCmec* cassette, which confers methicillin resistance and were classified as
159 methicillin-susceptible *S. aureus* (MSSA; n= 81/86; 94%) (**Figure 1C**).

160

161 Most of our isolates (n=48/86; 55.8%) were from community-acquired lineages
162 (MSSA or *SCCmec* types I, II, III), including CC30 which was the most common

163 clonal complex identified in our collection (n=14/86; 16.3%) (**Figure 1A+B**). In more
164 than three quarters (n=11/14; 78.6%,) of cases where this clonal complex was
165 identified, the patient was deemed to have had a good outcome and a "cured" status
166 (**Supplementary table S2**). A minority of isolates were identified from other CA-
167 lineages, CC8 (n=6) and CC59 (n=5), CC45 (n=9), CC7 (n=8), CC15 (n=6). No
168 isolates were sampled from two common pandemic CA- lineages, CC1 and CC80.

169

170 Many isolates we identified were from well described hospital-acquired lineages
171 (n=23/86; 26.7%), including the globally distributed CC5 lineage (n=12) (**Figure**
172 **1A+B**). Infections from this CC were often unresolved (n=6/12; 50%) and posed the
173 highest risk of a "not cured" patient outcome. CC22 is the most common sequence
174 type identified from clinical infections, particularly in the UK (51, 52), but was the 3rd
175 most sampled CC in our collection (n=11/86; 12.8%). This clonal complex was
176 implicated in a "not cured" patient outcome on only one occasion. All other CCs were
177 represented by fewer than 5 isolates. One isolate was isolated from the livestock
178 associated lineage, CC398 (n=1).

179

180 ***Accessory genome differences in ODRI isolates***

181 ODRI that leads to a "not cured" patient outcome is a complex process, which is
182 affected by genetic and environmental differences in the host (**Table 2**) as well as
183 variation in the infecting bacterial population. To investigate differences in gene
184 presence between isolates showing phenotypic variation, we further investigated
185 genes in the accessory genome. We characterized the pangenome using PIRATE
186 (53) with 86 isolates plus 8 reference strains (to help preserve gene nomenclature).
187 In total, PIRATE identified 4,142 gene clusters, of which over half were characterized
188 as core genes (present in 95% or more of the isolates; 2,150 genes; 52%). This was
189 consistent with core genome estimates from other *S. aureus* collections (54–57). The
190 accessory genome consisted of 1,992 genes (present in fewer than 95% of isolates),
191 representing ~48% of the pangenome. A large proportion of the accessory genome
192 (78%) was present in fewer than 25% of isolates (1,57/1,992 accessory genes;
193 **Supplementary table S3**). Core and accessory genome differences were visualized
194 in phandango (58) (**Figure S1A**). Consistent with the clonal nature of *S. aureus*,
195 isolates grouped by accessory genome content (using poppunk) clustered similarly to
196 the clonal frame (**Figure S1BC**) (59).

197

198 **Distribution of known virulence and AMR genes**

199 All *S. aureus* isolates were sampled from invasive disease cases and contained
200 many known virulence genes, with between 50 and 69 genes identified in each
201 isolate from the VfDB database (average: 63; update March 2021). Nearly half of
202 these putative virulence factors were present in all isolates (35 of 79; 44%), including
203 the genes: *adsA* (phagocytosis escape), *aur* (metalloproteinase), *geh* (lipase), *hla* (α -
204 hemolysin), *hlgAB* (γ -hemolysin), *hysA* (hyaluronate lysate), *icaABDR* (biofilm
205 formation), *isdAB* (surface proteins), *lip* (lipase), *srtB* (surface protein anchor),
206 *sspABC* (adhesion) and much of the *cap8* capsule operon (**Figure 2A**). Distribution
207 of virulence genes between the two clinical outcome groups ("cured" and "not cured")
208 was also considered. The methicillin resistance gene, *mecA* was more prevalent in
209 the "not cured" outcome group (n=2/21; 9.5%) compared to the "cured" group
210 (n=3/65; 4.6%). Also, the presence of the *bbp* gene (bone sialprotein binding)
211 (n=20/21; 95.2% versus n=58/65; 89.2%) and *ebpS* gene (elastin binding) (n=21/21;
212 100.0% versus n=60/65; 92.3%) were found to be more prevalent in the "not cured"
213 outcome group than in the "cured" outcome group, but this was not statistically
214 significant. (**Supplementary table S4**).

215

216 As most isolates were MSSA, there were very few antimicrobial resistance genes
217 (ARGs) identified through nucleotide comparisons with the AMRfinder Plus database
218 (**Supplementary table S5**). Differences were observed between clonal complexes
219 for the numbers of virulence and AMR determinants (**Figure 2B**). In common with
220 other studies, we identified slightly fewer virulence genes, but more ARGs in hospital-
221 associated lineages. On average there were 60.3 virulence genes and 4.4 ARGs in
222 HA lineages, compared with 63.8 virulence and 4.1 ARGs in community associated
223 lineages. Six MSSA clones were represented by three or more isolates, of which five
224 represented more than a third of our isolates (8 of 21; 38%) from patients who
225 experienced a "not cured" outcome (**Figure 2C**). Two clones posed a particularly
226 high risk to patients with 40% (2 of 5) of CC5-t002-MSSA and CC59-t216-MSSA
227 isolates developing a "not cured" patient outcome. A quarter of patients (2 of 8)
228 infected by CC7-t091-MSSA also experienced a "not cured" outcome, while those
229 infected by the CC22-t005-MSSA clone all recovered.

230

231 ***Both "cured" and "not cured" isolates induced high mortality in a *Galleria****
232 ***mellonella* model**

233 A selection of isolates (10 "not cured" and 10 "cured") were used to challenge *G.*
234 *mellonella* larvae. Bacterial suspensions were injected into larvae (average inoculum
235 of 2.75×10^6 CFU/larvae; range: 1.87×10^6 to 4.29×10^6) and incubated up to 120 hours.
236 However, high mortality was observed in a proportion of isolates in both outcome
237 groups (**Figure 3AB**). This may not be surprising as all isolates were from infection
238 cases, and all were found to possess at least 12 toxin genes. Further analysis of the
239 *Galleria* virulence results identified differences between the average mortality scores
240 when specific putative virulence genes were present (**Figure 3C**). Differences in
241 gene content between isolates were quantified and scored using SCOARY (60). We
242 report minus \log_{10} of the naïve p-value for the null hypothesis that the
243 presence/absence of this gene is unrelated to the trait status ($-\log_{10} > 2$ equivalent to
244 naïve p-value < 0.01). We identified four gene clusters associated with increased
245 killing during the *Galleria* infection model (**Figure 3D**). Three of which (g01257,
246 g01221 and g01491) demonstrated more than 90% sequence similarity with a SOS
247 response-activated pathogenicity island shared between *S. aureus* and *S.*
248 *epidermidis* isolates (SACOL0900-0904) (54, 61). The fourth gene cluster (g03516)
249 identified was identical (100% nucleotide similarity over 100% of the gene) to the
250 *msaC* gene (SACOL1438/SAUSA300_1296). As an uncoded member of the
251 *msaABCR* operon, this locus has an indirect role in virulence factors *aur*, *scp*, *ssp*
252 and *spl* and contributes to increased virulence, biofilm formation and triggers the
253 onset of bacterial persistence (62–64)(**Supplementary file S4**).

254

255 ***Isolate phenotypic variation may contribute to the onset of infection, but does***
256 ***little to influence patient outcome***

257 We tested laboratory phenotypes associated with increased virulence and compared
258 these with patient outcome. Individually, none of the phenotypes contributed
259 significantly to a "not cured" patient outcome (**Table 3**). Isolates were subject to
260 antimicrobial susceptibility profiling (29 antibiotics), biofilm formation, hemolysis
261 activity and staphyloxanthin production (**Supplementary table S6**). No isolate was
262 considered extensively or pan drug resistant, although 4 were considered multi-drug
263 resistant (resistant to three or more different classes of antibiotic). More than half
264 ($n=51/86$; 59.3 %) of all collected isolates were unable to form a thick biofilm under

265 laboratory conditions. Furthermore, 61.6 % (n=53/86) of all isolates produced
266 staphyloxanthin and 39.5 % (n=34/86) showed hemolytic activity (**Table 3**). Isolates
267 that demonstrated hemolytic activity contribute to a "cured" patient outcome ($\geq 90\%$
268 confidence; $p=0.090$, **Table 3**). Isolates that were able to produce a thick biofilm were
269 often also able to produce staphyloxanthin (n=27/35; 77.1%; **Table 4**). However, poor
270 biofilm forming isolates that produced staphyloxanthin (n=26/51; 51.0%) were
271 detrimentally associated with a "not cured" patient outcome (n=15/26; 57.7%).

272

273 **Genes associated with different virulence phenotypes**

274 Differences in gene content between phenotypes were quantified and scored using
275 SCOARY, reporting the minus \log_{10} of the naïve p-value for the null hypothesis that
276 the presence/absence of this gene is unrelated to the trait status ($-\log_{10}>2$ equivalent
277 to naïve p-value <0.01 ; **Supplementary table S7**). We identify genes associated with
278 six different phenotypes, including patient outcome, biofilm formation, hemolysis,
279 multi-drug resistance, methicillin resistance and staphyloxanthin production (**Figure**
280 **4**). An uncharacterized membrane protein (g02811) and a gene from the SA97
281 virulent bacteriophage (g03902) were associated with a "not cured" patient outcome
282 ($-\log_{10}>2$; naïve p-value <0.01 ; **Figure 4A**). Genes commonly found as part of the
283 *SCCmec* cassette (*mecA*, *paaZ*, *upgQ* and *mecRI*) were associated with methicillin
284 resistance, and were among the gene clusters that demonstrated the strongest
285 association with any phenotype ($-\log_{10}>6$; naïve p-value $<2 \times 10^{-7}$; **Figure 4B**). Several
286 hypothetical gene clusters were associated with biofilm formation (8 genes with naïve
287 p-value <0.01 ; $-\log_{10}>2$; **Figure 4C**).

288

289 The presence of several genes (27 genes with $-\log_{10}>2$, lowest p-value: 0.00017),
290 including enterotoxins A and D and the collagen adhesin *cna* were associated with
291 hemolysis production (**Figure 4D**). Despite only four isolates that were classed as
292 MDR, the presence of 93 genes (lowest p-value: 4.68×10^{-6}) were associated with
293 phenotypically measured MDR, which included several members of the *SCCmec*
294 cassette, the erythromycin resistance-associated *ermA* and the aminoglycoside
295 resistance determinant, *ant1* **Figure 4E**). Several enterotoxin genes were also
296 associated with MDR, along with the biofilm-associated gene *xerC*. The chemotaxis
297 inhibiting gene, *chp* was the only gene associated with staphyloxanthin production in
298 our dataset (**Figure 4F**).

299

300 **Genes linked to phenotypes that influence patient outcomes are more**
301 **recombinogenic**

302 Finally, we investigated the role of recombination in isolates that led to a poorer
303 patient outcome. On average, isolates that led to a "not cured" patient outcome
304 demonstrated the highest rates of recombination (**Figure S2**). However, genomes of
305 isolates from patients who were successfully 'cured' were predicted to have included
306 more recombination events. This is likely influenced by a small number of highly
307 recombinogenic genomes that were predicted to have undergone extensive
308 recombination (**Supplementary table S8**). Genes that were associated with any of
309 our tested phenotypes demonstrated greater clonal inheritance than genes in the
310 core genome. Meaning that phylogenies constructed from sequences of the
311 individual genes were consistent with the phylogeny constructed from the core
312 genome (**Figure 4G**). The mean consistency index (CI) was significantly higher
313 (Mann Whitney test; $U = 78998$, $p < 0.0001$) among virulence phenotype-associated
314 genes (0.7766 ± 0.2418) compared with the average for all core genes ($0.6943 \pm$
315 0.1408). Taken together, the highly clonal population structure of *S. aureus* (long
316 branches) – particularly those genes involved in virulence – and higher rates of
317 recombination between lineages permits co-evolution of several successful
318 hypervirulent lineages that can contribute to "not cured" patient outcomes in ODRI.

319 Discussion

320 Despite advances in many aspects of emergency and orthopedic trauma care, ODRI
321 persists as a challenge for the treating physicians and a significant burden for the
322 patient. The interaction between the host immune system and invading isolates is
323 complex and is not only affected by variation in host and bacterial genetics, but also
324 by factors such as host wellbeing and general health (e.g. obesity). In a similar way
325 to how the host deploys several different types of host defense mechanisms, bacteria
326 are armed with a toolbox of different virulence factors. We used a combination of
327 phenotype testing, an *in vivo* infection model and *in silico* genome characterization to
328 identify lineages and virulence factors that may contribute to the risk of poor patient
329 outcomes following ODRI.

330

331 Isolates from patients who experienced a "not cured" outcome did not cluster by core
332 or accessory genomes (**Figure 1A**). The most common clonal complex associated
333 with a poor patient outcome in our collection was CC5 (50%; **Figure 1B**). CC5 is
334 highly recombinogenic and able to infect multiple host species (65, 66) and is often
335 isolated from human infections, particularly skin and bone infections (55, 67). While
336 infection is often caused by MRSA, there is growing concern for the spread of
337 hypervirulent MSSA clones (67, 68). Nearly all the isolates we collected were
338 sensitive to methicillin and lacked a functional *SCCmec* cassette (9 of 12 CC5
339 isolates). The gain and loss of *SCCmec* cassettes by multiple *S. aureus* clones
340 continues to blur the differentiation of community-associated (CA) and hospital-
341 associated (HA) *S. aureus* lineages (69, 70).

342

343 Since the emergence and epidemic spread of USA300 (CC8) clone in the early
344 2000s (30, 71, 72), CA- lineages have dominated infection surveillance studies (19,
345 71, 72). CA- lineages are typically thought to carry larger - more cumbersome, and
346 less resistant - *SCCmec* types I, II and III, and often carry toxin genes such as the
347 PVL genes. While traditional HA-*S. aureus* lineages carry smaller *SCCmec* cassettes
348 that are more difficult to disrupt, which are maintained by successive generations.
349 Several HA-lineages rose to prominence around the world, only to have been
350 replaced as the most common lineages in human infections in specific regions;
351 including the rise of CC22 in the UK and Europe (18, 73–75), and replacement of HA-
352 MRSA-ST239 by CA-MRSA-ST59 in China (19). It has been suggested that

353 increased virulence, coupled with fewer putative AMR genes has contributed to the
354 success of these CA-clones/lineages (31, 76). This was the case in our collection
355 with more virulence genes and fewer ARGs found in CA-lineages compared to HA-
356 lineages (**Figure 2B & Table S5**).

357

358 Isolates from the most common European lineage (CC22) were common among our
359 collection of invasive isolates and were the most likely to lead to a "cured" patient
360 outcome (**Figure 1B**). Further characterization of the specific clones in our collection
361 identified 6 common clones, including a CC22-t005-MSSA clone that did not lead to a
362 "not cured" patient outcome in any of the 5 patients it infected (**Figure 2C**). The five
363 remaining clones that were identified in three or more patients were responsible for
364 more than a third of the "not cured" patient outcomes. The CC59-t216-MSSA and
365 CC5-t002-MSSA clones posed the highest risk, with 40% of patients infected by
366 these clones developing a poor outcome. The CC5-t002-MRSA clone has been
367 frequently observed, including studies from China and Iran where it exhibited
368 extensive mupirocin resistance, MDR and contained several virulence toxins (PVL
369 and *tsst-1*) (77, 78).

370

371 All isolates we collected were from invasive ODRI and contained at least 50 known
372 virulence genes (**Figure 2AB**). Infection is complex and the function of any virulence
373 gene is context dependent and a simple sum of the number of putative virulence
374 elements is unlikely to be a good proxy for the infective potential of an isolate. All
375 isolates in our collection were able to colonize and cause infection, but variation in
376 additional virulence factors will influence disease progression and host evasion.
377 Despite relatively small sample numbers, we were able to identify putative virulence-
378 associated genes from an *in vivo* infection model and phenotypic assays, including
379 biofilm production, antimicrobial susceptibility (and MDR), hemolysis and
380 staphyloxanthin production.

381

382 Similar assays in *S. epidermidis* identified biofilm formation as key to establishing an
383 ODRI through adhesion to implant surfaces (12, 43) and contributed towards a
384 poorer clinical outcome, persistence and recurrence (8). However, this was not the
385 case in the current study. Although 40% of the *S. aureus* isolates were able to form a
386 strong biofilm, no clear influence on patient outcome was observed (**Table 3**). Armed

387 with a suite of extracellular toxins, *S. aureus* can often cause more severe acute
388 infections (79), while *S. epidermidis* is often associated with less severe, chronic
389 infection – where strong biofilm formation on implants and dead tissue may be more
390 relevant (80–82). *In vitro* Staphyloxanthin production leads to increased pathogenicity
391 of *S. aureus* (83, 84), and 61% of our isolates were able to produce staphyloxanthin
392 (**Table S6**). This level of prevalence is consistent with the observation by Post *et al.*
393 whereby 56% of 305 isolates from implant and non-implant infections were
394 staphyloxanthin producers (85). The chemotaxis inhibitor protein (CHIPS), encoded
395 by *chp* was the only gene we found associated with staphyloxanthin production
396 (**Figure 4G**). CHIPS ability to help evade host immune responses pose the potential
397 for more severe and chronic infections (86, 87). Although it was not independently
398 associated with "not cured" in our study population.

399

400 In hypervirulent MSSA lineages and clones, increased carriage of virulence genes is
401 balanced against limited carriage of AMR genes. We observed this in our collection,
402 with relatively few isolates resistant to multiple antibiotics (**Figure 2B & Table S5**),
403 and lower rates of MRSA isolates compared to other studies (7% MRSA and 10%
404 MDR). Rates of MRSA (27% & 24%) were much higher in other studies of ODRI (10,
405 11). Both these previous studies involved patients with a median age above 60, and
406 patients infected with MRSA experienced lower cure rates (57%) than for MSSA-
407 infected patients (72%) or CoNS (82%) (10). Very high rates of methicillin resistance
408 have been observed in *S. epidermidis* ODRI isolates, which is consistent with
409 different modes of infection between the species (73% MRSE and 76% MDR) (8).
410 Elderly patients are more likely to suffer from infection with resistant bacteria due to
411 repeated hospital stays and multi-morbidity (88, 89), and may partially explain the
412 reduced number of MRSA isolates in our collection. Although only present in a small
413 number of our isolates (n=6; 7%), methicillin resistance was associated with a "not
414 cured" outcome (2 of 6; 33.3%; **Table 3**). This is consistent with many other studies
415 that have highlighted the detrimental effect of methicillin resistance on treatment
416 success (43, 55, 90).

417

418 Deep branching clades and highly structured clustering of isolates is evidence of the
419 strong selection pressures that have driven the evolution of *S. aureus*. Distinct *S.*
420 *aureus* lineages are found at markedly different prevalence globally, including

421 hypervirulent sub-lineages (74, 91). Waves of pandemic sub-lineages have been
422 described within CC30 - initially MSSA, before being replaced by MRSA variants (18,
423 19, 74). Independent acquisition of virulence determinants in these lineages was
424 associated with the rise and fall of these lineages and horizontal gene transfer (HGT)
425 likely has an important role in the accumulation of virulence factors. This lineage
426 specific accumulation of virulence genes makes traditional identification of virulence
427 factors difficult. Genome-wide association studies that can account for these lineage
428 effects (43, 44, 90, 92), or can differentiate between the types of association, are
429 potentially useful (93). Furthermore, the inclusion of the pangenome analyses
430 (including mobile elements and intergenic regions) and covarying SNPs and genes
431 (epistasis) (94, 95), combined with appropriate phenotypic validation and/or
432 transcriptome profiling will greatly enhance understanding of the contribution of
433 pathogen genetic variation on disease progression (49).

434

435 Infection is clearly a complex process influenced by the host immune system and
436 genotypic variation within the invading pathogen. Here, we only tested a single *S.*
437 *aureus* colony from each patient. However, there can be considerable diversity
438 among the commensal and infective isolates within a single person (96–99). Small
439 colony variants (SCV) (100, 101), persistence (102, 103) and dormancy (104, 105)
440 also help protect invading cells from the host immune system and evade
441 antimicrobial treatment. While the isolates collected here have already colonized host
442 subcutaneous tissue and established an infection, our aim was to delineate factors
443 that contribute to poorer patient outcomes. Our results are consistent with a complex
444 balance between virulence and colonization (32), involving core and accessory
445 genome elements, and provide some evidence that characterization of common
446 emerging clones and lineages may help disease outcome prediction.

447 **Materials and methods**

448

449 ***Clinical data and Staphylococcus aureus collection***

450 The clinical data and *S. aureus* collection was part of a prospective study performed
451 between November 2011 and September 2013 at BGU Murnau in Germany (12)
452 which was approved by the local ethical committee *Ethik-Kommission der*
453 *Bayerischen Landesärztekammer* under approval number 12063 and registered with
454 <https://clinicaltrials.gov> with identifier NCT02971657. All patients enrolled in the study
455 were aged 18 or older and provided informed written consent. Patient inclusion
456 criteria were culture-positive *S. aureus* infection involving fracture related infection
457 (FRI) or periprosthetic joint infections (PJI). All patient details were anonymized, and
458 *S. aureus* isolates given genome database identifiers (BIGSids), study identifiers
459 (ARI-number) and sample laboratory identifiers (Lab-ID). Associated clinical data are
460 summarized in **Table S1**. After an average of 23 months follow-up (FUP) patients
461 were assessed for treatment outcome. When patients did not complete a follow-up
462 appointment, the clinical outcome was assessed at the time of hospital discharge.
463 "Cured" patients were free of infection, surgical and systemic antibiotic therapy had
464 ceased with function of the affected joint or limb restored. If one or more of these
465 parameters were negative, patients were considered to have had a "not cured"
466 outcome (8, 12).

467

468 ***Genome sequencing and assembly***

469 *S. aureus* colonies were cultured in 5 ml Tryptone Soy Broth at 37 °C with overnight
470 shaking. DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Germany)
471 according to manufacturer's instructions with the addition of 1.5 µg/µL lysostaphin
472 (Sigma-Aldrich, Buchs, Switzerland) and 2 µg/ml lysozyme (Sigma-Aldrich, Buchs,
473 Switzerland) to facilitate cell lysis. DNA was quantified using a spectrophotometer
474 prior to sending for sequencing by Microsynth AG (Switzerland) using an Illumina
475 MiSeq benchtop sequencer. Sequencing libraries were prepared using Nextera XT
476 library preparation kits (v2) and paired end 250 bp reads generated with the MiSeq
477 run kit (v2). Short read paired-end data was assembled *de novo* with SPAdes
478 (version 3.3.0; using the *-careful* command)(106) and assessed for quality (n=86
479 genomes contained < 500 contigs). Average assembled genomes were 2,771,938 bp

480 in length (range: 2,638,312 - 2,962,075 bp) consisting of 113 contigs (range: 29 –
481 358 contigs) with an N50 of 43,492 bp (range: 5,729 – 109,980) (**Table S2**).

482

483 ***Genome archiving, multiple genome alignments and construction of isolate*** 484 ***genealogies***

485 An alignment of all 86 *S. aureus* isolates was constructed from concatenated gene
486 sequences of all core genes (found in ≥95% isolates) using MAFFT (version 7)(107)
487 on a gene-by-gene basis (size: 2,138,455 bp; **Supplementary file 1**). A maximum-
488 likelihood phylogenies were constructed using a GTR + I + G substitution model and
489 ultra-fast bootstrapping (1,000 bootstraps) implemented in IQ-TREE (version
490 2.0.3)(108, 109) and visualized on Microreact: [https://microreact.org/project/Post-
491 Pascoe-Saureus/0f0c26fb](https://microreact.org/project/Post-Pascoe-Saureus/0f0c26fb) (**Supplementary file S3**) (110). Collection also shared on
492 the pathogen watch website ([https://pathogen.watch/collection/7rgjyrzz3xoc-post-
493 and-pascoe-et-al-2022-hypervirulent-mssa-from-odri](https://pathogen.watch/collection/7rgjyrzz3xoc-post-and-pascoe-et-al-2022-hypervirulent-mssa-from-odri)).

494

495 ***Molecular typing and genome characterization***

496 Our publicly available BIGSdb database (<https://sheppardlab.com/resources/>)
497 includes functionality to determine multi-locus sequence type (MLST) profiles defined
498 by the Staphylococcal pubMLST database (<https://pubmlst.org/saureus>; accessed
499 March 2019) (111). Staphopia (version 1.0.0) was used to define *SCCmec* types
500 (112) and *spa* types were typed *in silico* using spaTyper v1.0 (**Supplementary table**
501 **S2**) (113).

502

503 ***Care and accessory genome characterization***

504 All unique genes present in at least one of our isolates (or eight reference strains)
505 were identified by automated annotation using PROKKA (version 1.13) followed by
506 PIRATE, a pangenomics tool that allows for orthologue gene clustering in bacteria
507 (**Supplementary table S3; Supplementary file S3**). Genes families in PIRATE were
508 defined using a wide range of amino acid percentage sequence identity thresholds
509 for Markov Cluster algorithm (MCL) clustering (45, 50, 60, 70, 80, 90, 95, 98). Core
510 genes were defined as present in 95% of the genomes and accessory genes as
511 present in at least one isolate (**Supplementary figure S1A**). The pangenome was
512 visualized using phandango, as a matrix of gene presence alongside a core genome
513 phylogeny (58). Pairwise core and accessory genome distances were compared

514 using PopPunk (version 1.1.4), which uses pairwise nucleotide k-mer comparisons to
515 distinguish shared sequence and gene content to identify divergence of the
516 accessory genome in relation to the core genome. A two-component Gaussian
517 mixture model was used to construct a network to define clusters and visualized with
518 microreact (**Supplementary figure S1BC**) (59, 110).

519

520 ***Identification of known virulence traits and antimicrobial resistance genes***

521 The presence of putative virulence factors and antimicrobial resistance genes were
522 identified from assembled genomes using ABRICATE (v0.3) (59). Putative virulence
523 genes were detected through comparison with reference nucleotide sequences in the
524 VfDb (default settings: $\geq 70\%$ identity over $\geq 50\%$ of the gene; **Supplementary table**
525 **S4**) (114). Antimicrobial resistance genes were identified using the NCBI AMRfinder
526 Plus (115) and CARD (116) databases (19th April, 2020 update). Results for both
527 AMR databases were similar, with the CARD database identifying additional AMR
528 associated genes. We report the results from the curated AMRfinder Plus database
529 (**Supplementary table S5**).

530

531 ***Phenotype testing***

532 ***Antibiotic susceptibility testing:*** Minimum inhibitory concentrations (MICs) for 29
533 antibiotics were determined using a Vitek2 machine (bioMérieux Vitek Inc., USA) as
534 described previously (8, 12). Susceptibility breakpoints were defined according to the
535 definitions of the European Committee of Antimicrobial Susceptibility Testing
536 (EUCAST) and isolates resistant to 3 or more antimicrobial classes were defined as
537 multidrug resistant (MDR)(118). The Vitek2 results for oxacillin and cefoxitin were
538 used as a proxy for methicillin-resistance. ***Staphyloxanthin production:***
539 Staphyloxanthin production indicated by a yellow-orange pigmentation of *S. aureus*
540 colonies as well as ***Haemolysin activity:*** Haemolysis activity of *S. aureus* strains
541 was evaluated as previously described (119). ***Biofilm formation:*** was also assayed
542 as described previously (8, 12, 85, 120). Association amongst and between the
543 clinical parameters, bacterial phenotypes, clades and presence/absence of genes
544 were analyzed statistically using Chi-square test. Statistical analyses were performed
545 using SPSS (Version 23, IBM, USA) or GraphPad prism 6 (GraphPad Software, Inc.;
546 **Supplementary table S6**).

547

548 ***In vivo virulence and survival assay in Galleria mellonella larvae:*** The
549 invertebrate *G. mellonella* infection model was used to study the virulence of the *S.*
550 *aureus* strains as previously described (121, 122). *G. mellonella* were obtained at
551 pre-larval stage (Entomos AG, Zurich Switzerland). Larvae were grown at 30 °C in
552 the dark and groups of ten larvae in the final instar larval stage weighing 200–
553 400 mg were used in all assays. A bacterial suspension of 10⁶ CFU/ml was
554 prepared. Quantitative culture of a sample from each bacterial suspension was
555 performed immediately after preparation by ten-fold serial dilution and plating on
556 Tryptone Soy Agar plates to check the actual total viable count of the prepared
557 suspension. Bacterial inoculates (10 µl) were injected into the last left pro-leg into the
558 hemocoel of the last-instar larvae (200-400 mg). After injection, larvae were
559 incubated at 37 °C in the dark. Larvae were assessed daily for survival up to 5 days
560 post-injection and were evaluated according to survival, being scored as dead when
561 they displayed no movement in response to touch. Controls included a group of
562 larvae that did not receive any injection and a group of larvae inoculated with sterile
563 phosphate-buffered saline (PBS). Experiments consisted of 10 larvae per bacterial
564 strain, which was repeated in three separate experiments. For *G. mellonella* survival
565 analysis, larvae mean survival curves were plotted using the Kaplan-Meier method
566 (GraphPad Prism 6, USA; **Supplementary table S6**).

567

568 ***Pan-genome-wide association studies of phenotype variation***

569 Pangenome-wide differences in gene presence were quantified using the genome-
570 wide association software, SCOARY (version 1.6.14)(60). With only limited numbers
571 of samples in our collection, we report phylogenetically naïve differences in gene
572 presence between clinical and laboratory symptoms and phenotypes
573 (**Supplementary table S7**).

574

575 **Recombination and allelic consistency**

576 The number of polymorphisms introduced by mutation and recombination in the core
577 genome were inferred using Gubbins (version 2.4.1)(123) for each isolate (per
578 branch; **Supplementary table S8**). The consistency of the phylogenetic tree to
579 patterns of variation in sequence alignments for each gene of interest was calculated
580 as before (124, 125). Consistency indices for each single-gene alignment of 130
581 virulence-associated genes to a phylogeny constructed using an alignment of 2,150

582 core genes shared by 94 isolates, were calculated using the CI function of the R
583 Phangorn package (126).

584

585 **Data availability**

586 Illumina short read sequence data are archived on the Sequence Read Archive
587 associated with BioProject accession PRJNA529795. All assembled genomes are
588 shared on figshare (doi: 10.6084/m9.figshare.7926866) and are available on our
589 public Staphylococcal Bacterial Isolate Genome Sequence Database (BIGSdb):
590 <https://sheppardlab.com/resources/>. Isolate genealogy with associated meta-data is
591 visualized on microreact (110): [https://microreact.org/project/Post-Pascoe-](https://microreact.org/project/Post-Pascoe-Saureus/0f0c26fb)
592 [Saureus/0f0c26fb](https://microreact.org/project/Post-Pascoe-Saureus/0f0c26fb). All high-performance computing was performed on MRC CLIMB
593 (127) in a bioconda environment (128).

594

595 **Acknowledgements**

596 This work was funded by AO Trauma as part of the Clinical Priority Program, Bone
597 Infection. All high-performance computing was performed on MRC CLIMB, funded by
598 the Medical Research Council (MR/L015080/1 & MR/T030062/1). This publication
599 made use of the PubMLST website (<http://pubmlst.org/>) developed by Keith Jolley
600 and Martin Maiden (129) and sited at the University of Oxford. The development of
601 that website was funded by the Wellcome Trust. The funders had no role in study
602 design, data collection and interpretation, or the decision to submit the work for
603 publication.

604

605 All authors report no conflicts of interest relevant to this article.

606

607 **Contributions**

608 Conceptualization: VP, BP, SKS, and TFM; Isolate collection: VP, CE, JF, MM, and
609 TFM; Data collection and curation: VP, BP, MDH and SKS; Formal Analysis: VP, BP,
610 EM, JKC; Visualization: VP, BP, EM, JKC; Writing – original draft: VP, BP, SKS and
611 TFM; Writing – Review & Editing: VP, BP, SKS and TFM; Funding Acquisition: VP,
612 RGR and TFM.

613

614 **Figures and Table legends**

615 **Table 1:** Collection overview.

616 **Table 2:** Patient risk factors.

617 **Table 3:** Infection isolate prognostic phenotypes.

618 **Table 4:** Phenotype associations in combination with enhanced biofilm formation.

619

620 **Figure 1:**

621 **Population structure of *S. aureus* isolates collected in this study. A:** A
622 maximum-likelihood phylogeny was constructed with IQ-TREE, using a GTR model
623 and ultrafast bootstrapping (1000 bootstraps; version 2.0.3)(108, 109) from an
624 alignment of all isolates (n=86). Scale bar represents a genetic distance of 0.001.
625 Leaves from isolates that were "cured" are white (n=65) and those that did not
626 achieve a "cured" status are black (n=21). The tree is annotated with MLST, clonal
627 complex, methicillin resistance status, *SCCmec* and *spa* types and the presence of
628 PVL genes (indicated by colored blocks). Isolates from hospital associated lineages

629 are highlighted in blue. Interactive visualization is available on Microreact (110):
630 <https://microreact.org/project/Post-Pascoe-Saureus/0f0c26fb>. The number of isolates
631 from each **(B)** MLST clonal complexes (CC) and **(C)** methicillin resistant (MRSA) and
632 methicillin susceptible (MSSA) lineages. The proportion of isolates that lead to a "not
633 cured" status is shown in black.

634

635 **Figure 2:**

636 **Hypervirulent lineages and clones. A:** Maximum-likelihood phylogeny of our 86 *S.*
637 *aureus* isolates above matrix of defined virulence factors identified using the VfDb
638 (114). Summary boxplots of the number of virulence and antimicrobial resistance
639 genes (ARGs) identified in each **(B)** clonal complex and **(C)** MSSA clone
640 (represented by 3 or more isolates). All data points shown, bars show min and max.
641 Hospital-associated lineages and clones highlighted in blue. The number of isolates
642 from each MSSA clone is also shown, with the proportion of isolates from patients
643 who did not achieve a "cured" status in black.

644

645 **Figure 3:**

646 ***Galleria mellonella* virulence model.** Kaplan-Meier survival curve of larvae infected
647 with *S. aureus* isolates from **A:** "not cured" outcome patients and from **B:** "cured"
648 outcome patients. Each line represents a different *S. aureus* isolate injected into 10
649 larvae per isolate. Mean survival rate was calculated per isolate. Dotted line
650 represents survival of larvae injected with PBS; green line represents high survival
651 rate and red line indicates a high mortality rate. **C:** Mean kill curve scores from
652 isolates that contained each virulence factor identified by VfDb. **D:** Pangenome-wide
653 association study comparing isolates with high kill score (above 50% at 120 hrs) vs
654 those with low kills scores using SCOARY (60). No lineage correction was used and
655 the phylogenetically naïve minus LOG p-value reported. Three genes from previously
656 identified pathogenicity island and *msaC* gene from the *msaABCR* operon were
657 associated with increased killing.

658

659 **Figure 4:**

660 **Pangenome-wide association studies.** SCOARY was used to quantify gene
661 presence between isolates tested for six targeted virulence phenotypes (60). No
662 lineage correction was used, and the phylogenetically naïve minus LOG p-value

663 reported. Isolates were scored for phenotypic differences in **(A)** patient outcome; **(B)**
664 methicillin resistance; **(C)** biofilm formation; **(D)** hemolysis; **(E)** multidrug resistance;
665 and **(F)** staphyloxanthin production. Genes that were highly associated with a given
666 phenotype are labelled. Multiple toxin (blue circles) and *SCCmec* cassette (red
667 circles) genes were associated with more than one phenotype. **(G)** Individual gene
668 phylogenies were compared to a core phylogeny for each virulence phenotype-
669 associated gene and consistency indices calculated. The two distributions were
670 significantly different (Mann Whitney test; $U = 78998$, $p < 0.0001$) between virulence
671 phenotype-associated genes (0.7766 ± 0.2418) compared with the average for all
672 core genes (0.6943 ± 0.1408).

673

674 **Supplementary material** (figshare: <https://doi.org/10.6084/m9.figshare.7926866>)

675 **Table S1:** Demographic data collected for each isolate.

676 **Table S2:** Genome quality control and extended typing results.

677 **Table S3:** Summary of core and accessory genome characterization with PIRATE.

678 **Table S4:** Summary of genes identified by screening known virulence genes with the
679 VfDB.

680 **Table S5:** Summary of genes identified by screening antibiotic resistance genes with
681 the AMRfinder (NCBI) and CARD databases.

682 **Table S6:** Summary of virulence phenotype data.

683 **Table S7:** Summary of genes associated with virulence phenotypes (SCOARY).

684 **Table S8:** Per isolate recombination statistics using Gubbins.

685

686 **Figure S1:** Accessory genome characterization.

687 **Figure S2:** Recombination analysis.

688

689 **Supplementary file 1:** Contigs

690 **Supplementary file 2:** Alignment.

691 **Supplementary file 3:** Phylogeny (.nwk) of 86 collected isolates.

692 **Supplementary file 4:** PIRATE pangenome gene families.

693

694 **References**

- 695 1. Tschudin-Sutter S, Frei R, Dangel M, Jakob M, Balmelli C, Schaefer DJ,
696 Weisser M, Elzi L, Battegay M, Widmer AF. 2016. Validation of a treatment
697 algorithm for orthopaedic implant-related infections with device-retention—
698 results from a prospective observational cohort study. *Clin Microbiol Infect*
699 22:457.e1-457.e9.
- 700 2. Zimmerli W. 2014. Clinical presentation and treatment of orthopaedic implant-
701 associated infection. *J Intern Med*.
- 702 3. Moriarty TF, Kuehl R, Coenye T, Metsemakers W-JJ, Morgenstern M, Schwarz
703 EM, Riool M, Zaat SAJJ, Khana N, Kates SL, Geoff Richards R, Richards RG.
704 2016. Orthopaedic device-related infection: Current and future interventions for
705 improved prevention and treatment. *EFORT Open Rev* 1:89–99.
- 706 4. Li B, Webster TJ. 2018. Bacteria antibiotic resistance: New challenges and
707 opportunities for implant-associated orthopedic infections. *J Orthop Res* 36:22–
708 32.
- 709 5. PATZAKIS MJ, WILKINS J. 1989. Factors Influencing Infection Rate in Open
710 Fracture Wounds. *Clin Orthop Relat Res* 243.
- 711 6. Boxma H, Broekhuizen T, Patka P, Oosting H. 1996. Randomised controlled
712 trial of single-dose antibiotic prophylaxis in surgical treatment of closed
713 fractures: The Dutch Trauma Trial. *Lancet* 347:1133–1137.
- 714 7. Spiegl U, Friederichs J, Pätzold R, Militz M, Josten C, Bühren V. 2013. Risk
715 factors for failed two-stage procedure after chronic posttraumatic periprosthetic
716 hip infections. *Arch Orthop Trauma Surg* 133:421–428.
- 717 8. Morgenstern M, Post V, Erichsen C, Hungerer S, Bühren V, Militz M, Richards
718 RG, Moriarty TF. 2016. Biofilm formation increases treatment failure in
719 *Staphylococcus epidermidis* device-related osteomyelitis of the lower extremity
720 in human patients. *J Orthop Res* 34:1905–1913.
- 721 9. Guo G, Wang J, You Y, Tan J, Shen H. 2017. Distribution characteristics of
722 *Staphylococcus* spp. in different phases of periprosthetic joint infection: A
723 review. *Exp Ther Med* 13:2599.
- 724 10. Teterycz D, Ferry T, Lew D, Stern R, Assal M, Hoffmeyer P, Bernard L, Uçkay
725 I. 2010. Outcome of orthopedic implant infections due to different
726 staphylococci. *Int J Infect Dis* 14.
- 727 11. Kilgus DJ, Howe DJ, Strang A. 2002. Results of Periprosthetic Hip and Knee

- 728 Infections Caused by Resistant Bacteria. *Clin Orthop Relat Res* 404:116–124.
- 729 12. Post V, Harris LG, Morgenstern M, Mageiros L, Hitchings MD, Méric G, Pascoe
730 B, Sheppard SK, Richards RG, Moriarty TF. 2017. Comparative Genomics
731 Study of *Staphylococcus epidermidis* Isolates from Orthopedic-Device-Related
732 Infections Correlated with Patient Outcome. *J Clin Microbiol* 55:3089–3103.
- 733 13. Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. 2005. Etiology of
734 implant orthopedic infections: A survey on 1027 clinical isolates. *Int J Artif*
735 *Organs* 28:1091–1100.
- 736 14. Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection
737 related to orthopedic devices and issues of antibiotic resistance. *Biomaterials*
738 27:2331–2339.
- 739 15. Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L,
740 Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a
741 prevalent ribocluster of methicillin-sensitive *Staphylococcus aureus* from
742 Orthopedic implant infections. Correspondence with MLST CC30. *Front Cell*
743 *Infect Microbiol* 6:8.
- 744 16. Otto M. 2012. Methicillin-resistant *Staphylococcus aureus* infection is
745 associated with increased mortality. <http://dx.doi.org/102217/fmb11156> 7:189–
746 191.
- 747 17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Zhu
748 Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core genome
749 allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility
750 prediction. *Microb Genomics* 7:000610.
- 751 18. Chambers HF, DeLeo FR. 2009. Waves of Resistance: *Staphylococcus aureus*
752 in the Antibiotic Era. *Nat Rev Microbiol* 7:629.
- 753 19. Chen H, Yin Y, van Dorp L, Shaw LP, Gao H, Acman M, Yuan J, Chen F, Sun
754 S, Wang X, Li S, Zhang Y, Farrer RA, Wang H, Balloux F. 2021. Drivers of
755 methicillin-resistant *Staphylococcus aureus* (MRSA) lineage replacement in
756 China. *Genome Med* 13:1–14.
- 757 20. Harkins CP, Pichon B, Doumith M, Parkhill J, Westh H, Tomasz A, de
758 Lencastre H, Bentley SD, Kearns AM, Holden MTG. 2017. Methicillin-resistant
759 *Staphylococcus aureus* emerged long before the introduction of methicillin into
760 clinical practice. *Genome Biol* 18:1–11.
- 761 21. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus

- 762 sequence typing for characterization of methicillin-resistant and methicillin-
763 susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol* 38:1008–1015.
- 764 22. Feil EJ, Cooper JE, Grundmann H, Robinson DA, Enright MC, Berendt T,
765 Peacock SJ, Smith JM, Murphy M, Spratt BG, Moore CE, Day NPJ. 2003. How
766 clonal is *Staphylococcus aureus*? *J Bacteriol* 185:3307–3316.
- 767 23. Urwin R, Maiden MCJ. 2003. Multi-locus sequence typing: a tool for global
768 epidemiology. *Trends Microbiol* 11:479–487.
- 769 24. Tenover FC, Goering R V. 2009. Methicillin-resistant *Staphylococcus aureus*
770 strain USA300: origin and epidemiology. *J Antimicrob Chemother* 64:441–446.
- 771 25. Ito T, Hiramatsu K, Oliveira DC, De Lencastre H, Zhang K, Westh H, O'Brien F,
772 Giffard PM, Coleman D, Tenover FC, Boyle-Vavra S, Skov RL, Enright MC,
773 Kreiswirth B, Kwan SK, Grundmann H, Laurent F, Sollid JE, Kearns AM,
774 Goering R, John JF, Daum R, Soderquist B. 2009. Classification of
775 staphylococcal cassette chromosome mec (SCCmec): Guidelines for reporting
776 novel SCCmec elements. *Antimicrob Agents Chemother* 53:4961–4967.
- 777 26. Strommenger B, Bräulke C, Heuck D, Schmidt C, Pasemann B, Nübel U, Witte
778 W. 2008. spa Typing of *Staphylococcus aureus* as a Frontline Tool in
779 Epidemiological Typing. *J Clin Microbiol* 46:574.
- 780 27. Koeck M, Como-Sabetti K, Boxrud D, Dobbins G, Glennen A, Anacker M,
781 Jawahir S, See I, Lynfield R. 2019. Burdens of Invasive Methicillin-Susceptible
782 and Methicillin-Resistant *Staphylococcus aureus* Disease, Minnesota, USA.
783 *Emerg Infect Dis* 25:171.
- 784 28. David MZ, Boyle-Vavra S, Zychowski DL, Daum RS. 2011. Methicillin-
785 Susceptible *Staphylococcus aureus* as a Predominantly Healthcare-Associated
786 Pathogen: A Possible Reversal of Roles? *PLoS One* 6.
- 787 29. Otto M. 2013. Community-associated MRSA: What makes them special? *Int J*
788 *Med Microbiol* 303:324–330.
- 789 30. Uhlemann AC, Otto M, Lowy FD, DeLeo FR. 2014. Evolution of community-
790 and healthcare-associated methicillin-resistant *Staphylococcus aureus*. *Infect*
791 *Genet Evol* 21:563–574.
- 792 31. Laabei M, Uhlemann AC, Lowy FD, Austin ED, Yokoyama M, Ouadi K, Feil E,
793 Thorpe HA, Williams B, Perkins M, Peacock SJ, Clarke SR, Dordel J, Holden
794 M, Votintseva AA, Bowden R, Crook DW, Young BC, Wilson DJ, Recker M,
795 Massey RC. 2015. Evolutionary Trade-Offs Underlie the Multi-faceted

- 796 Virulence of *Staphylococcus aureus*. *PLOS Biol* 13:e1002229.
- 797 32. Sheppard SK. 2022. Strain wars and the evolution of opportunistic pathogens.
798 *Curr Opin Microbiol* 67.
- 799 33. Otto M. 2012. MRSA virulence and spread. *Cell Microbiol* 14:1513–1521.
- 800 34. Otto M. 2010. Basis of virulence in community-associated methicillin-resistant
801 *Staphylococcus aureus*. *Annu Rev Microbiol* 64:143–162.
- 802 35. Archer GL. 1998. *Staphylococcus aureus*: a well-armed pathogen. *Clin Infect*
803 *Dis* 26:1179–1181.
- 804 36. Arciola CR, Visai L, Testoni F, Arciola S, Campoccia D, Speziale P, Montanaro
805 L. 2011. Concise survey of *Staphylococcus aureus* virulence factors that
806 promote adhesion and damage to peri-implant tissues. *Int J Artif Organs*
807 34:771–780.
- 808 37. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. 1999.
809 Distribution of genes encoding resistance to macrolides, lincosamides, and
810 streptogramins among staphylococci. *Antimicrob Agents Chemother* 43:1062–
811 1066.
- 812 38. Mehrotra M, Wang G, Johnson WM. 2000. Multiplex PCR for detection of
813 genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock
814 syndrome toxin 1, and methicillin resistance. *J Clin Microbiol* 38:1032–1035.
- 815 39. Kobras CM, Fenton AK, Sheppard SK. 2021. Next-generation microbiology:
816 from comparative genomics to gene function. *Genome Biol* 2021 22:1–16.
- 817 40. Sheppard SK, Guttman DS, Fitzgerald JR. 2018. Population genomics of
818 bacterial host adaptation. *Nat Rev Genet* 19:549–565.
- 819 41. Méric G, Yahara K, Mageiros L, Pascoe B, Maiden MCJ, Jolley KA, Sheppard
820 SK. 2014. A reference pan-genome approach to comparative bacterial
821 genomics: Identification of novel epidemiological markers in pathogenic
822 *Campylobacter*. *PLoS One* 9.
- 823 42. Recker M, Laabei M, Toleman MS, Reuter S, Saunderson RB, Blane B, Török
824 ME, Ouadi K, Stevens E, Yokoyama M, Steventon J, Thompson L, Milne G,
825 Bayliss S, Bacon L, Peacock SJ, Massey RC. 2017. Clonal differences in
826 *Staphylococcus aureus* bacteraemia-associated mortality. *Nat Microbiol*
827 2:1381–1388.
- 828 43. Méric G, Mageiros L, Pensar J, Laabei M, Yahara K, Pascoe B, Kittiwon N,
829 Tadee P, Post V, Lamble S, Bowden R, Bray JE, Morgenstern M, Jolley KA,

- 830 Maiden MCJ, Feil EJ, Didelot X, Miragaia M, de Lencastre H, Moriarty TF,
831 Rohde H, Massey RC, Mack D, Corander J, Sheppard SK. 2018. Disease-
832 associated genotypes of the commensal skin bacterium *Staphylococcus*
833 *epidermidis*. *Nat Commun* 9.
- 834 44. Laabei M, Recker M, Rudkin JK, Aldeljawi M, Gulay Z, Sloan TJ, Williams P,
835 Endres JL, Bayles KW, Fey PD, Yajjala VK, Widhelm T, Hawkins E, Lewis K,
836 Parfett S, Scowen L, Peacock SJ, Holden M, Wilson D, Read TD, Van Den
837 Elsen J, Priest NK, Feil EJ, Hurst LD, Josefsson E, Massey RC. 2014.
838 Predicting the virulence of MRSA from its genome sequence. *Genome Res*
839 24:839–849.
- 840 45. Gordon NC, Price JR, Cole K, Everitt R, Morgan M, Finney J, Kearns AM,
841 Pichon B, Young B, Wilson DJ, Llewelyn MJ, Paul J, Peto TEA, Crook DW,
842 Walker AS, Golubchik T. 2014. Prediction of *staphylococcus aureus*
843 antimicrobial resistance by whole-genome sequencing. *J Clin Microbiol*
844 52:1182–1191.
- 845 46. Berthenet E, Yahara K, Thorell K, Pascoe B, Meric G, Mikhail JM, Engstrand L,
846 Enroth H, Burette A, Megraud F, Varon C, Atherton JC, Smith S, Wilkinson TS,
847 Hitchings MD, Falush D, Sheppard SK. 2018. A GWAS on *Helicobacter pylori*
848 strains points to genetic variants associated with gastric cancer risk. *BMC Biol*
849 <https://doi.org/10.1186/s12915-018-0550-3>.
- 850 47. Hwang W, Yong JH, Min KB, Lee KM, Pascoe B, Sheppard SK, Yoon SS.
851 2021. Genome-wide association study of signature genetic alterations among
852 *pseudomonas aeruginosa* cystic fibrosis isolates. *PLoS Pathog* 17.
- 853 48. Peters S, Pascoe B, Wu Z, Bayliss SC, Zeng X, Edwinson A, Veerabadrhan-
854 Gurunathan S, Jawahir S, Calland JK, Mourkas E, Patel R, Wiens T, Decuir M,
855 Boxrud D, Smith K, Parker CT, Farrugia G, Zhang Q, Sheppard SK, Grover M.
856 2021. *Campylobacter jejuni* genotypes are associated with post-infection
857 irritable bowel syndrome in humans. *Commun Biol* 4.
- 858 49. Sassi M, Bronsard J, Pascreau G, Emily M, Donnio P-Y, Revest M, Felden B,
859 Wirth T, Augagneur Y. 2022. Forecasting *Staphylococcus aureus* Infections
860 Using Genome-Wide Association Studies, Machine Learning, and
861 Transcriptomic Approaches. *mSystems*
862 <https://doi.org/10.1128/MSYSTEMS.00378-22>.
- 863 50. Aanensen DM, Feil EJ, Holden MTG, Dordel J, Yeats CA, Fedosejev A, Goater

- 864 R, Castillo-Ramírez S, Corander J, Colijn C, Chlebowicz MA, Schouls L, Heck
865 M, Pluister G, Ruimy R, Kahlmeter G, Åhman J, Matuschek E, Friedrich AW,
866 Parkhill J, Bentley SD, Spratt BG, Grundmann J, Krziwanek K, Stumvoll S,
867 Koller W, Denis O, Struelens M, Nashev D, Budimir A, Kalenic S, Pieridou-
868 Bagatzouni D, Jakubu V, Zemlickova H, Westh H, Larsen AR, Skov R, Laurent
869 F, Ettienne J, Strommenger B, Witte W, Vourli S, Vatopoulos A, Vainio A,
870 Vuopio-Varkila J, Fuzi M, Ungvári E, Murchan S, Rossney A, Miklasevics E,
871 Balode A, Haraldsson G, Kristinsson KG, Monaco M, Pantosti A, Borg M, Van
872 Santen-Verheuvél M, Huijsdens X, Marstein L, Jacobsen T, Simonsen GS,
873 Airesde-Sousa M, De Lencastre H, Luczak-Kadlubowska A, Hryniewicz W,
874 Straut M, Codita I, Perez-Vazquez M, Iglesias JO, Spik VC, Mueller-Premru M,
875 Haeggman S, Olsson-Liljequist B, Ellington M, Kearns A. 2016. Whole-genome
876 sequencing for routine pathogen surveillance in public health: A population
877 snapshot of invasive *Staphylococcus aureus* in Europe. *MBio* 7.
- 878 51. Garvey MI, Bradley CW, Holden KL, Oppenheim B. 2017. Outbreak of clonal
879 complex 22 Panton-Valentine leucocidin-positive methicillin-resistant
880 *Staphylococcus aureus*. *J Infect Prev* 18:224–230.
- 881 52. de Vos AS, de Vlas SJ, Lindsay JA, Kretzschmar MEE, Knight GM. 2021.
882 Understanding MRSA clonal competition within a UK hospital; the possible
883 importance of density dependence. *Epidemics* 37:100511.
- 884 53. SC B, HA T, NM C, SK S, EJ F. 2019. PIRATE: A fast and scalable
885 pangenomics toolbox for clustering diverged orthologues in bacteria.
886 *Gigascience* 8.
- 887 54. Méric G, Miragaia M, De Been M, Yahara K, Pascoe B, Mageiros L, Mikhail J,
888 Harris LG, Wilkinson TS, Rolo J, Lamble S, Bray JE, Jolley KA, Hanage WP,
889 Bowden R, Maiden MCJ, Mack D, De Lencastre H, Feil EJ, Corander J,
890 Sheppard SK. 2015. Ecological overlap and horizontal gene transfer in
891 *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Genome Biol Evol* 7.
- 892 55. Manara S, Pasolli E, Dolce D, Ravenni N, Campana S, Armanini F, Asnicar F,
893 Mengoni A, Galli L, Montagnani C, Venturini E, Rota-Stabelli O, Grandi G,
894 Taccetti G, Segata N. 2018. Whole-genome epidemiology, characterisation,
895 and phylogenetic reconstruction of *Staphylococcus aureus* strains in a
896 paediatric hospital. *Genome Med* 2018 10:1–19.
- 897 56. Moller AG, Robert A, Petit I, Read TD. 2022. Species-Scale Genomic Analysis

- 898 of *Staphylococcus aureus* Genes Influencing Phage Host Range and Their
899 Relationships to Virulence and Antibiotic Resistance Genes. *mSystems* 7.
900 57. Suzuki H, Lefébure T, Bitar PP, Stanhope MJ. 2012. Comparative genomic
901 analysis of the genus *Staphylococcus* including *Staphylococcus aureus* and its
902 newly described sister species *Staphylococcus simiae*. *BMC Genomics* 13:38.
903 58. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR.
904 2018. Phandango: An interactive viewer for bacterial population genomics.
905 *Bioinformatics* <https://doi.org/10.1093/bioinformatics/btx610>.
906 59. Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW, Weiser JN, Corander
907 J, Bentley SD, Croucher NJ. 2019. Fast and flexible bacterial genomic
908 epidemiology with PopPUNK. *Genome Res* 29:304–316.
909 60. Brynildsrud O, Bohlin J, Scheffer L, Eldholm V. 2016. Rapid scoring of genes in
910 microbial pan-genome-wide association studies with Scoary. *Genome Biol*
911 17:238.
912 61. Anderson KL, Roberts C, Disz T, Vonstein V, Hwang K, Overbeek R, Olson
913 PD, Projan SJ, Dunman PM. 2006. Characterization of the *Staphylococcus*
914 *aureus* Heat Shock, Cold Shock, Stringent, and SOS Responses and Their
915 Effects on Log-Phase mRNA Turnover. *J Bacteriol* 188:6739.
916 62. C BG, Sahukhal GS, Elasri MO. 2022. Delineating the Role of the *msaABCR*
917 Operon in *Staphylococcal* Overflow Metabolism. *Front Microbiol* 13:914512.
918 63. Sahukhal GS, Elasri MO. 2014. Identification and characterization of an
919 operon, *msaABCR*, that controls virulence and biofilm development in
920 *Staphylococcus aureus*. *BMC Microbiol* 14:154.
921 64. Pandey S, Sahukhal GS, Elasri MO. 2021. The *msaABCR* Operon Regulates
922 Persister Formation by Modulating Energy Metabolism in *Staphylococcus*
923 *aureus*. *Front Microbiol* 12:881.
924 65. Murray S, Pascoe B, Méric G, Mageiros L, Yahara K, Hitchings MD, Friedmann
925 Y, Wilkinson TS, Gormley FJ, Mack D, Bray JE, Lamble S, Bowden R, Jolley
926 KA, Maiden MCJ, Wendlandt S, Schwarz S, Corander J, Fitzgerald JR,
927 Sheppard SK. 2017. Recombination-Mediated Host Adaptation by Avian
928 *Staphylococcus aureus*. *Genome Biol Evol* 9:830–842.
929 66. Lowder B V., Guinane CM, Zakour NLB, Weinert LA, Conway-Morris A,
930 Cartwright RA, Simpson AJ, Rambaut A, Nübel U, Fitzgerald JR. 2009. Recent
931 human-to-poultry host jump, adaptation, and pandemic spread of

- 932 Staphylococcus aureus. Proc Natl Acad Sci U S A 106:19545–19550.
- 933 67. Jian Y, Zhao L, Zhao N, Lv HY, Liu Y, He L, Liu Q, Li M. 2021. Increasing
934 prevalence of hypervirulent ST5 methicillin susceptible Staphylococcus aureus
935 subtype poses a serious clinical threat. Emerg Microbes Infect 10:109.
- 936 68. Nübel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, Huang YC, Coombs G,
937 Ip M, Westh H, Skov R, Struelens MJ, Goering R V., Strommenger B, Weller A,
938 Witte W, Achtman M. 2008. Frequent emergence and limited geographic
939 dispersal of methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U
940 S A 105:14130–14135.
- 941 69. Bal AM, Coombs GW, Holden MTG, Lindsay JA, Nimmo GR, Tattevin P, Skov
942 RL. 2016. Genomic insights into the emergence and spread of international
943 clones of healthcare-, community- and livestock-associated methicillin-resistant
944 Staphylococcus aureus: Blurring of the traditional definitions. J Glob Antimicrob
945 Resist 6:95–101.
- 946 70. Hsu LY, Harris SR, Chlebowicz MA, Lindsay JA, Koh TH, Krishnan P, Tan TY,
947 Hon PY, Grubb WB, Bentley SD, Parkhill J, Peacock SJ, Holden MTG. 2015.
948 Evolutionary dynamics of methicillin-resistant Staphylococcus aureus within a
949 healthcare system. Genome Biol 16:1–13.
- 950 71. Kong EF, Johnson JK, Jabra-Rizk MA. 2016. Community-Associated
951 Methicillin-Resistant Staphylococcus aureus: An Enemy amidst Us. PLOS
952 Pathog 12:e1005837.
- 953 72. Strauß L, Stegger M, Akpaka PE, Alabi A, Breurec S, Coombs G, Egyir B,
954 Larsen AR, Laurent F, Monecke S, Peters G, Skov R, Strommenger B,
955 Vandenesch F, Schaumburg F, Mellmann A. Origin, evolution, and global
956 transmission of community-acquired Staphylococcus aureus ST8
957 <https://doi.org/10.1073/pnas.1702472114>.
- 958 73. Wyllie DH, Walker AS, Miller R, Moore C, Williamson SR, Schlackow I, Finney
959 JM, O'Connor L, Peto TEA, Crook DW. 2011. Decline of methicillin-resistant
960 Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded
961 infection-control intensification. BMJ Open 1:e000160.
- 962 74. Holden MTG, Hsu LY, Kurt K, Weinert LA, Mather AE, Harris SR, Strommenger
963 B, Layer F, Witte W, De Lencastre H, Skov R, Westh H, Žemličková H,
964 Coombs G, Kearns AM, Hill RLR, Edgeworth J, Gould I, Gant V, Cooke J,
965 Edwards GF, McAdam PR, Templeton KE, McCann A, Zhou Z, Castillo-

- 966 Ramírez S, Feil EJ, Hudson LO, Enright MC, Balloux F, Aanensen DM, Spratt
967 BG, Fitzgerald JR, Parkhill J, Achtman M, Bentley SD, Nübel U. 2013. A
968 genomic portrait of the emergence, evolution, and global spread of a
969 methicillin-resistant *Staphylococcus aureus* pandemic. *Genome Res* 23:653–
970 664.
- 971 75. Aires-de-Sousa M, Correia B, De Lencastre H, Alves V, Branca F, Cabral L,
972 Clemente J, Daniel I, Faustino A, Ferreira E, Lameiras C, Lopes J, Marques J,
973 Peres I, Ribeiro G, Sancho L, Santos O, Santos P, Vaz MT, Videira Z. 2008.
974 Changing patterns in frequency of recovery of five methicillin-resistant
975 *Staphylococcus aureus* clones in Portuguese hospitals: Surveillance over a 16-
976 year period. *J Clin Microbiol* 46:2912–2917.
- 977 76. Gill JL, Hedge J, Wilson DJ, MacLean RC. 2021. Evolutionary Processes
978 Driving the Rise and Fall of *Staphylococcus aureus* ST239, a Dominant Hybrid
979 Pathogen. *MBio* <https://doi.org/10.1128/MBIO.02168-21>.
- 980 77. Wang M, Zheng Y, Mediavilla JR, Chen L, Kreiswirth BN, Song Y, Yang R, Du
981 H. 2017. Hospital Dissemination of *tst-1*-Positive Clonal Complex 5 (CC5)
982 Methicillin-Resistant *Staphylococcus aureus*. *Front Cell Infect Microbiol* 7.
- 983 78. Goudarzi M, Razeghi M, Chirani AS, Fazeli M, Tayebi Z, Pouriran R. 2020.
984 Characteristics of methicillin-resistant *Staphylococcus aureus* carrying the toxic
985 shock syndrome toxin gene: high prevalence of clonal complex 22 strains and
986 the emergence of new *spa* types *t223* and *t605* in Iran. *New Microbes New*
987 *Infect* 36:100695.
- 988 79. Brescó MS, Harris LG, Thompson K, Stanic B, Morgenstern M, O'Mahony L,
989 Richards RG, Moriarty TF. 2017. Pathogenic mechanisms and host interactions
990 in *Staphylococcus epidermidis* device-related infection. *Front Microbiol* 8:1401.
- 991 80. Fey PD, Olson ME. 2010. Current concepts in biofilm formation of
992 *Staphylococcus epidermidis*. *Future Microbiol* 5:917.
- 993 81. Mack D. 1999. Molecular mechanisms of *Staphylococcus epidermidis* biofilm
994 formation. *J Hosp Infect* 43:S113–S125.
- 995 82. Harris LG, Murray S, Pascoe B, Bray J, Meric G, Magerios L, Wilkinson TS,
996 Jeeves R, Rohde H, Schwarz S, De Lencastre H, Miragaia M, Rolo J, Bowden
997 R, Jolley KA, Maiden MCJ, Mack D, Sheppard SK. 2016. Biofilm Morphotypes
998 and Population Structure among *Staphylococcus epidermidis* from Commensal
999 and Clinical Samples. *PLoS One* 11.

- 1000 83. Clauditz A, Resch A, Wieland KP, Peschel A, Götz F. 2006. Staphyloxanthin
1001 Plays a Role in the Fitness of *Staphylococcus aureus* and Its Ability To Cope
1002 with Oxidative Stress. *Infect Immun* 74:4950.
- 1003 84. Xue L, Chen YY, Yan Z, Lu W, Wan D, Zhu H. 2019. Staphyloxanthin: a
1004 potential target for antivirulence therapy. *Infect Drug Resist* 12:2151.
- 1005 85. Post V, Wahl P, Uçkay I, Ochsner P, Zimmerli W, Corvec S, Loiez C, Richards
1006 RG, Moriarty TF. 2014. Phenotypic and genotypic characterisation of
1007 *Staphylococcus aureus* causing musculoskeletal infections. *Int J Med Microbiol*
1008 304:565–576.
- 1009 86. Rooijackers SHM, Ruyken M, van Roon J, van Kessel KPM, van Strijp JAG,
1010 van Wamel WJB. 2006. Early expression of SCIN and CHIPS drives instant
1011 immune evasion by *Staphylococcus aureus*. *Cell Microbiol* 8:1282–1293.
- 1012 87. De Haas CJC, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJB,
1013 Heezius ECJM, Poppelier MJG, Van Kessel KPM, Van Strijp JAG. 2004.
1014 Chemotaxis Inhibitory Protein of *Staphylococcus aureus*, a Bacterial
1015 Antiinflammatory Agent. *J Exp Med* 199:687.
- 1016 88. Uçkay I, Teterycz D, Ferry T, Harbarth S, Lübbecke A, Emonet S, Chilcott M,
1017 Hoffmeyer P, Bernard L. 2009. Poor utility of MRSA screening to predict
1018 staphylococcal species in orthopaedic implant infections. *J Hosp Infect* 73:89–
1019 91.
- 1020 89. Ferry T, Uçkay I, Vaudaux P, François P, Schrenzel J, Harbarth S, Laurent F,
1021 Bernard L, Vandenesch F, Etienne J, Hoffmeyer P, Lew D. 2010. Risk factors
1022 for treatment failure in orthopedic device-related methicillin-resistant
1023 *Staphylococcus aureus* infection. *Eur J Clin Microbiol Infect Dis* 29:171–180.
- 1024 90. Young BC, Wu C-H, Charlesworth J, Earle S, Price JR, Gordon NC, Cole K,
1025 Dunn L, Liu E, Oakley S, Godwin H, Fung R, Miller R, Knox K, Votintseva A,
1026 Quan TP, Tilley R, Scarborough M, Crook DW, Peto TE, Walker AS, Llewelyn
1027 MJ, Wilson DJ. 2021. Antimicrobial resistance determinants are associated
1028 with *Staphylococcus aureus* bacteraemia and adaptation to the healthcare
1029 environment: a bacterial genome-wide association study. *Microb Genomics*
1030 7:700.
- 1031 91. Castillo-Ramírez S, Corander J, Marttinen P, Aldeljawi M, Hanage WP, Westh
1032 H, Boye K, Gulay Z, Bentley SD, Parkhill J, Holden MT, Feil EJ. 2012.
1033 Phylogeographic variation in recombination rates within a global clone of

- 1034 methicillin-resistant *Staphylococcus aureus*. *Genome Biol* 13:1–13.
- 1035 92. Earle SG, Wu C-H, Charlesworth J, Stoesser N, Gordon NC, Walker TM,
1036 Spencer CCA, Iqbal Z, Clifton DA, Hopkins KL, Woodford N, Smith EG, Ismail
1037 N, Llewelyn MJ, Peto TE, Crook DW, McVean G, Walker AS, Wilson DJ. 2016.
1038 Identifying lineage effects when controlling for population structure improves
1039 power in bacterial association studies. *Nat Microbiol* 1:16041.
- 1040 93. Collins C, Didelot X. 2018. A phylogenetic method to perform genome-wide
1041 association studies in microbes that accounts for population structure and
1042 recombination. *PLoS Comput Biol* 14.
- 1043 94. Taylor AJ, Méric G, Yahara K, Pascoe B, Mageiros L, Mourkas E, Calland JK,
1044 Puranen S, Hitchings MD, Jolley KA, Kobras CM, Williams NJ, Vliet AHM van,
1045 Parkhill J, Maiden MCJ, Corander J, Hurst LD, Falush D, Didelot X, Kelly DJ,
1046 Sheppard SK. 2022. A two-hit epistasis model prevents core genome
1047 disharmony in recombining bacteria. *bioRxiv* 2021.03.15.435406.
- 1048 95. Yokoyama M, Stevens E, Laabei M, Bacon L, Heesom K, Bayliss S, Ooi N,
1049 O'Neill AJ, Murray E, Williams P, Lubben A, Reeksting S, Méric G, Pascoe B,
1050 Sheppard SK, Recker M, Hurst LD, Massey RC. 2018. Epistasis analysis
1051 uncovers hidden antibiotic resistance-associated fitness costs hampering the
1052 evolution of MRSA. *Genome Biol* 19.
- 1053 96. Paterson GK, Harrison EM, Murray GGR, Welch JJ, Warland JH, Holden MTG,
1054 Morgan FJE, Ba X, Koop G, Harris SR, Maskell DJ, Peacock SJ, Herrtage ME,
1055 Parkhill J, Holmes MA. 2015. Capturing the cloud of diversity reveals
1056 complexity and heterogeneity of MRSA carriage, infection and transmission.
1057 *Nat Commun* 2015 6:1–10.
- 1058 97. Didelot X, Walker AS, Peto TE, Crook DW, Wilson DJ. 2016. Within-host
1059 evolution of bacterial pathogens. *Nat Rev Microbiol*. Nature Publishing Group.
- 1060 98. Golubchik T, Batty EM, Miller RR, Farr H, Young BC, Lerner-Svensson H, Fung
1061 R, Godwin H, Knox K, Votintseva A, Everitt RG, Street T, Cule M, Ip CLC,
1062 Didelot X, Peto TEA, Harding RM, Wilson DJ, Crook DW, Bowden R. 2013.
1063 Within-Host Evolution of *Staphylococcus aureus* during Asymptomatic
1064 Carriage. *PLoS One* 8.
- 1065 99. Young BC, Golubchik T, Batty EM, Fung R, Lerner-Svensson H, Votintseva
1066 AA, Miller RR, Godwin H, Knox K, Everitt RG, Iqbal Z, Rimmer AJ, Cule M, Ip
1067 CLC, Didelot X, Harding RM, Donnelly P, Peto TE, Crook DW, Bowden R,

- 1068 Wilsona DJ. 2012. Evolutionary dynamics of *Staphylococcus aureus* during
1069 progression from carriage to disease. *Proc Natl Acad Sci* 109:4550–4555.
- 1070 100. Kahl BC. 2014. Small colony variants (SCVs) of *Staphylococcus aureus* – A
1071 bacterial survival strategy. *Infect Genet Evol* 21:515–522.
- 1072 101. Loss G, Simões PM, Valour F, Cortês MF, Gonzaga L, Bergot M, Trouillet-
1073 Assant S, Josse J, Diot A, Ricci E, Vasconcelos AT, Laurent F. 2019.
1074 *Staphylococcus aureus* Small Colony Variants (SCVs): News From a Chronic
1075 Prosthetic Joint Infection. *Front Cell Infect Microbiol* 9:363.
- 1076 102. Peyrusson F, Varet H, Nguyen TK, Legendre R, Sismeiro O, Coppée JY, Wolz
1077 C, Tenson T, Van Bambeke F. 2020. Intracellular *Staphylococcus aureus*
1078 persists upon antibiotic exposure. *Nat Commun* 2020 11:1–14.
- 1079 103. Lechner S, Lewis K, Bertram R. 2012. *Staphylococcus aureus* Persists
1080 Tolerant to Bactericidal Antibiotics. *Microb Physiol* 22:235–244.
- 1081 104. Pascoe B, Dams L, Wilkinson TS, Harris LG, Bodger O, Mack D, Davies AP.
1082 2014. Dormant cells of *Staphylococcus aureus* are resuscitated by spent
1083 culture supernatant. *PLoS One* 9.
- 1084 105. Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, Clair G,
1085 Adkins JN, Cheung AL, Lewis K. 2016. Persister formation in *Staphylococcus*
1086 *aureus* is associated with ATP depletion. *Nat Microbiol* 1.
- 1087 106. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin
1088 VM, Nikolenko SI, Pham S, Pribelski AD, Pyshkin A V., Sirotkin A V., Vyahhi
1089 N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A New Genome
1090 Assembly Algorithm and Its Applications to Single-Cell Sequencing. *J Comput*
1091 *Biol* 19:455–477.
- 1092 107. Katoh K, Standley DM. 2013. MAFFT Multiple Sequence Alignment Software
1093 Version 7: Improvements in Performance and Usability. *Mol Biol Evol* 30:772–
1094 780.
- 1095 108. Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. 2015. IQ-TREE: A Fast
1096 and Effective Stochastic Algorithm for Estimating Maximum-Likelihood
1097 Phylogenies. *Mol Biol Evol* 32:268–274.
- 1098 109. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. 2018. UFBoot2:
1099 Improving the Ultrafast Bootstrap Approximation. *Mol Biol Evol* 35:518–522.
- 1100 110. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ,
1101 Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016.


- 1102 Microreact: visualizing and sharing data for genomic epidemiology and
1103 phylogeography. *Microb Genomics* 2.
- 1104 111. Jolley KA, Bray JE, Maiden MCJ. 2018. Open-access bacterial population
1105 genomics: BIGSdb software, the PubMLST.org website and their applications.
1106 Wellcome open Res 3.
- 1107 112. Petit RA, Read TD. 2018. *Staphylococcus aureus* viewed from the perspective
1108 of 40,000+ genomes. *PeerJ* 2018:e5261.
- 1109 113. Bartels MD, Petersen A, Worning P, Nielsen JB, Lerner-Svensson H, Johansen
1110 HK, Andersen LP, Jarløv JO, Boye K, Larsen AR, Westh H. 2014. Comparing
1111 Whole-Genome Sequencing with Sanger Sequencing for spa Typing of
1112 Methicillin-Resistant *Staphylococcus aureus*. *J Clin Microbiol* 52:4305.
- 1113 114. Chen L, Zheng D, Liu B, Yang J, Jin Q. 2016. VFDB 2016: Hierarchical and
1114 refined dataset for big data analysis - 10 years on. *Nucleic Acids Res* 44:D694–
1115 D697.
- 1116 115. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH,
1117 Zhao S, Hsu C-H, McDermott PF, Tadesse DA, Morales C, Simmons M,
1118 Tillman G, Wasilenko J, Folster JP, Klimke W. 2019. Using the NCBI
1119 AMRFinder Tool to Determine Antimicrobial Resistance Genotype-Phenotype
1120 Correlations Within a Collection of NARMS Isolates. *bioRxiv* 550707.
- 1121 116. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A,
1122 Huynh W, Nguyen A-L V, Cheng AA, Liu S, Min SY, Miroshnichenko A, Tran H-
1123 K, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M,
1124 Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk
1125 HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL,
1126 Hsiao WWL, Domselaar G V, McArthur AG. 2019. CARD 2020: antibiotic
1127 resistome surveillance with the comprehensive antibiotic resistance database.
1128 *Nucleic Acids Res* <https://doi.org/10.1093/nar/gkz935>.
- 1129 117. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local
1130 alignment search tool. *J Mol Biol* 215:403–410.
- 1131 118. EFSA/ECDC. 2019. European Food Safety Authority and European Centre for
1132 Disease Prevention and Control. The European Union summary report on
1133 antimicrobial resistance in zoonotic and indicator bacteria from humans,
1134 animals and food in 2017. *EFSA J* 17:5598.
- 1135 119. Herbert S, Ziebandt AK, Ohlsen K, Schäfer T, Hecker M, Albrecht D, Novick R,

- 1136 Götz F. 2010. Repair of Global Regulators in *Staphylococcus aureus* 8325 and
1137 Comparative Analysis with Other Clinical Isolates. *Infect Immun* 78:2877.
- 1138 120. Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Ćirković I,
1139 Ruzicka F. 2007. Quantification of biofilm in microtiter plates: overview of
1140 testing conditions and practical recommendations for assessment of biofilm
1141 production by staphylococci. *APMIS* 115:891–899.
- 1142 121. Ignasiak K, Maxwell A. 2017. *Galleria mellonella* (greater wax moth) larvae as
1143 a model for antibiotic susceptibility testing and acute toxicity trials. *BMC Res*
1144 *Notes* 10:428.
- 1145 122. Desbois AP, Coote PJ. 2011. Wax moth larva (*Galleria mellonella*): an in vivo
1146 model for assessing the efficacy of antistaphylococcal agents. *J Antimicrob*
1147 *Chemother* 66:1785–1790.
- 1148 123. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD,
1149 Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of
1150 recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids*
1151 *Res* 43:e15–e15.
- 1152 124. Mageiros L, Méric G, Bayliss SC, Pensar J, Pascoe B, Mourkas E, Calland JK,
1153 Yahara K, Murray S, Wilkinson TS, Williams LK, Hitchings MD, Porter J,
1154 Kemmett K, Feil EJ, Jolley KA, Williams NJ, Corander J, Sheppard SK. 2021.
1155 Genome evolution and the emergence of pathogenicity in avian *Escherichia*
1156 *coli*. *Nat Commun* 12.
- 1157 125. Mourkas E, Florez-Cuadrado D, Pascoe B, Calland JK, Bayliss SC, Mageiros
1158 L, Méric G, Hitchings MD, Quesada A, Porrero C, Ugarte-Ruiz M, Gutiérrez-
1159 Fernández J, Domínguez L, Sheppard SK. 2019. Gene pool transmission of
1160 multidrug resistance among *Campylobacter* from livestock, sewage and human
1161 disease. *Environ Microbiol* <https://doi.org/10.1111/1462-2920.14760>.
- 1162 126. Schliep KP. 2011. phangorn: phylogenetic analysis in R. *Bioinformatics*
1163 27:592–593.
- 1164 127. Connor TR, Loman NJ, Thompson S, Smith A, Southgate J, Poplawski R, Bull
1165 MJ, Richardson E, Ismail M, Thompson SE-, Kitchen C, Guest M, Bakke M,
1166 Sheppard SK, Pallen MJ. 2016. CLIMB (the Cloud Infrastructure for Microbial
1167 Bioinformatics): an online resource for the medical microbiology community.
1168 *Microb Genomics* 2.
- 1169 128. Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH,


- 1170 Valieris R, Köster J. 2018. Bioconda: sustainable and comprehensive software
1171 distribution for the life sciences. *Nat Methods* 15:475–476.
1172 129. Jolley KA, Maiden MCJ. 2010. BIGSdb: Scalable analysis of bacterial genome
1173 variation at the population level. *BMC Bioinformatics* 11:595.
1174
1175

A


medRxiv preprint doi: <https://doi.org/10.1101/2022.10.21.22280349>; this version posted October 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






B



C









Table 1: Cohort description

Total, n (%)	Complete study cohort	
	86	(100%)
<i>Clinical course and infection outcome, n (%)</i>		
Multiple revision surgeries	83	96.5%
Cured	65	75.6%
<i>Health status, n (%)</i>		
Obesity	25	29.1%
Smoking	28	32.6%
Diabetes	16	18.6%
Chronic immunosuppression	11	12.8%
<i>Infection characteristics, n (%)</i>		
Peri-prosthetic joint infection	19	22.1%
Acute infection	25	29.1%
Open fracture (initially)	21	24.4%
<i>Type of implant, n (%)</i>		
Peri-prosthetic joint infection (PJI)	19	22.1%
Nail	19	22.1%
Plate	36	41.9%
Screw	6	7.0%
Fixateur externe	4	4.7%
K-wire	1	1.2%
Ligament reconstruction device	1	1.2%

Table 2: Patient risk factors

Prognostic factor	Cured outcome				p-value
	No		Yes		
	n=	(%)	n=	(%)	
Total	21	24.4%	65	75.6%	
Obesity					0.295
No	13	21.3%	48	78.7%	
Yes	8	32.0%	17	68.0%	
Smoking					0.931
No	14	24.1%	44	75.9%	
Yes	7	25.0%	21	75.0%	
Diabetes mellitus					0.559
No	18	25.7%	52	74.3%	
Yes	3	18.8%	13	81.3%	
Chronic immunosuppression					0.606
No	19	25.3%	56	74.7%	
Yes	2	18.2%	9	81.8%	
Open fracture (initially)					0.510
No	17	26.2%	48	73.8%	
Yes	4	19.0%	17	81.0%	
Acute infection					0.541
No	16	26.2%	45	73.8%	
Yes	5	20.0%	20	80.0%	
Multiple revision surgeries					0.316
No	0	0.0%	3	100.0%	
Yes	21	25.3%	62	74.7%	

Table 3: Phenotypic risk factors

<i>S. aureus</i> phenotype	Cured outcome				p-value
		No	Yes		
		n=	(%)	n=	(%)
Total		21	24.4%	65	75.6%
<i>Biofilm formation</i>					0.429
	No	14	27.5%	37	72.5%
	Yes	7	20.0%	28	80.0%
<i>Staphyloxanthin production</i>					0.976
	No	8	24.2%	25	75.8%
	Yes	13	24.5%	40	75.5%
<i>Hemolysis activity</i>					0.090 **
	No	16	30.8%	36	69.2%
	Yes	5	14.7%	29	85.3%
<i>Methicillin resistance</i>					0.598
	No	19	23.8%	61	76.3%
	Yes	2	33.3%	4	66.7%
<i>Aminoglycoside resistance</i>					0.077 *
	No	20	23.5%	65	76.5%
	Yes	1	100.0%	0	0.0%
<i>Multi-drug resistance</i>					0.139
	No	17	22.1%	60	77.9%
	Yes	4	44.4%	5	55.6%

Table 4: Phenotype associations in combination with enhanced biofilm formation

	Cured outcome	
	No	Yes
	n (%)	n (%)
Total	21 (24.4)	65 (75.6)
Biofilm formation		
Positive (n=35; 40.7%)	7 (20.0)	28 (80.0)
Multi-drug resistance		
Yes (n=5; 14.3%)	2 (40.0)	3 (60.0)
No (n=30; 85.7%)	5 (16.7)	25 (83.3)
Methicillin resistance		
Yes (n=1; 2.9%)	0 (0)	1 (100)
No (n=34; 97.1%)	7 (20.6)	27 (79.4)
Haemolytic activity		
Yes (n=10; 28.6%)	0 (0)	10 (100)
No (n=25; 71.4%)	7 (28.0)	18 (72.0)
Staphyloxanthin production		
Yes (n=27; 77.1%)	4 (22.2)	14 (77.8)
No (n=8; 22.9%)	2 (25.0)	6 (75.0)
Negative (n=51; 59.3%)	14 (27.5)	37 (72.5)
Multi-drug resistance		
Yes (n=4; 7.8%)	2 (50.0)	2 (50.0)
No (n=47; 92.2%)	12 (25.5)	35 (74.5)
Methicillin resistance		
Yes (n=5; 9.8%)	2 (40.0)	3 (60.0)
No (n=46; 90.2%)	12 (26.1)	34 (73.9)
Haemolytic activity		
Yes (n=24; 47.1%)	21 (87.5)	3 (12.5)
No (n=27; 52.9%)	25 (92.6)	2 (7.4)
Staphyloxanthin production		
Yes (n=26; 51.0%)	15 (57.7)	11 (42.3)
No (n=25; 49.0%)	12 (48.0)	13 (52.0)